The Myeloma 2016 meeting: Integrating science and clinical practice
New aims and next steps for adult ALL induction therapy
The prognostic value of IDH1 and IDH2 in acute myeloid leukemia (AML)
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
A registry for AML in pregnancy - why it is important